# Semaglutide and a higher resting heart rate

Resting heart rate can rise during semaglutide treatment. A wearable trend is useful context, but symptoms and clinical assessment matter.

Canonical: https://velri.co/blog/semaglutide-resting-heart-rate-watch-data-newcomer
Publisher: Velri (https://velri.co/about)
Published: 2026-07-14
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Semaglutide's approved labeling reports increases in resting heart rate. A new upward trend on a watch is therefore relevant to the prescribing provider, but it does not show the cause or significance by itself. [1]

The label calls for heart-rate monitoring and for patients to report palpitations or a racing heartbeat while resting. For a sustained increase, the label instructs clinicians to discontinue treatment. The prescribing provider should assess the change and direct the response. [1]

## Compare similar readings

A watch reading during a walk is not comparable with a resting reading. A useful record identifies the device, time, activity and whether symptoms were present. Keeping that context helps prevent an isolated number from becoming a misleading trend.

A wearable can bring a concern to attention. The label calls for clinical monitoring of heart rate, including assessment of a sustained increase. [1]

## Report the experience as well as the number

“Racing while sitting still” and “my weekly average moved slightly” are different reports. Include when the change began, whether it followed a treatment change and whether there has been vomiting, diarrhea or difficulty maintaining fluids. Dehydration is a separate concern in semaglutide's safety labeling. [1]

A provider may need to check the pulse, review other medicines and assess possible contributors before deciding what the trend means.

## Do not build a self-adjustment rule from trial averages

The average change reported in a trial is not a personal safety cutoff. It does not mean that every smaller change can be ignored or that every larger change proves harm.

The useful response is to review a persistent resting change and any associated symptoms, following the medication's safety instructions. A dose should not be adjusted independently to make a watch score return to its previous value. [1]

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support